(2,4-二硝基苯基)肼,硫酸 | 61155-51-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2,4-二硝基苯基)肼,硫酸
• 英文名称: 2,4-dinitrophenylhydrazine sulphate
• 英文别名: solfato di 2,4-dinitrofenilidrazina；2,4-dinitrophenylhydrazine sulfate；2,4-dinitrophenyl-hydrazine-sulphuric acid；Sulfuric acid--(2,4-dinitrophenyl)hydrazine (1/1)；(2,4-dinitrophenyl)hydrazine;sulfuric acid
• CAS: 61155-51-9
• 化学式: C₆H₆N₄O₄*H₂O₄S
• 分子量: 296.218
• InChiKey: CHZDTZAJKIIRMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.14
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  213
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  1,1-dibutoxy-3-ethoxy-3-methyl-butane 、 (2,4-二硝基苯基)肼,硫酸 生成 3-methyl-crotonaldehyde-(2,4-dinitro-phenylhydrazone)
  参考文献：
  名称：

  Makin,S.M. et al., Journal of general chemistry of the USSR, 1962, vol. 32, p. 2492 - 2499

  摘要：

  DOI：
• 作为试剂：
  描述：

  1,1-diethoxy-2,4,6-octatriene 在 magnesium monohydrogen phosphate 、 sodium silicate 、 (2,4-二硝基苯基)肼,硫酸 作用下， 生成 2,4,6-辛三烯醛
  参考文献：
  名称：

  Makin,S.M.; Sudakova,V.S., Journal of general chemistry of the USSR, 1962, vol. 32, p. 3107 - 3111

  摘要：

  DOI：

文献信息

• Reactions of (E)-(3-Aryl-3-oxoprop-1-en-1-yl)triphenylphosphonium Bromides with Arylhydrazines
  作者：R. Dzh. Khachikyan、Z. G. Ovakimyan、E. O. Karamyan、G. A. Panosyan

  DOI：10.1134/s1070363219020087

  日期：2019.2

  (E)-(3-Aryl-3-oxoprop-1en-1-yl)triphenylphosphonium bromides reacted with arylhydrazines in an acidic medium to form hydrazones, the intramolecular heterocyclization of which led to the formation of (2,5- diaryl-2,3-dihydro-1H-pyrazol-3-yl)triphenylphosphonium bromides. Under the action of hydrobromic acid, the resulting quaternary phosphonium salts produced saturated (3-aryl-3-oxopropyl)triphenylphosphonium salts.

  （E）-（3- ary l-3- ox op r.-1 e n-1- yl）triph en yl phosphonium bromides与 aryl hydraz ines在酸性介质中反应生成 hy draz ones，其中内分子环合化导致形成（2,5- diary l-2,3-d i h y dr o-1 H-p y rz a l-3- yl）triph en yl phosphonium bromides。在此溴酸作 us 的作用下，获得 quaternary磷 酸 盐的产物为饱和的（3- ary l-3- ox op r -yl）triph en yl phosphonium盐。
• The reaction of iron pentacarbonyl with 6-aminofulvenes: Some organic chemistry ofR,S andR,R/R,S-[Fe2η, η-C5H4CH(NMe2)CH(NMe2)C5H4) (CO)2(μ-CO)2]
  作者：Brian Callan、M. Gary Cox、Anita McCabe、A.R. Manning、Pardeep Sayal、Paul Soye、Stephen C. Wade、F.S. Stephens、P. McArdle、D. Cunningham

  DOI：10.1016/0022-328x(94)88045-x

  日期：1994.2

  extensive organic chemistry that leaves the Fe2(CO)2(μ-CO)2 moieties intact. There are differences between1 and2, due to conventional stereochemical effects, and consequently the Fe2(CO)2(μ-CO)2 fragments are involved in some instances; this leads to unexpected and unusual reactions. The structures of2 and the ketone [Fe2(η,η-C5H4CH2C(O)C5H4(CO)2(μ-CO)2] have been confirmed by X-ray diffraction studies

  在回流的二甲苯6- dimethylaminofulvene五羰基铁反应，得到三种产物，1，2和3。化合物1是- [R ，小号- [铁2 η，η-C 5 H ^ 4 CH（NME 2）CH（NME 2）C 5 H ^ 4（CO）2（μ-C0）2 ]，2是它的- [R ，- [R /小号，š异构体，和3是的[Fe 2 η 3，η 5 -Me2 NCHC 5 H 3 CHC 5 H 4（CO）5 ]。高反应物浓度和过量的[Fe（CO）5 ]有利于化合物3。的类似物2和3，但不是1可以通过使用6-ME（PH）NCHC来制备5 ħ 4，6-ET 2 NCHC 5 ħ 4和6-我镨2 NCHC 5 ħ 4 ; 这些最后还给出了未连接的二聚物[Feη 5 -C 5 H ^ 4CH 2 N i Pr 2 2（CO）2（μ-CO）2 ]。该行为归因于NR 2基团对形成环状CC键的空间影响。动态NMR研究表
• 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
  申请人：——

  公开号：US20040002513A1

  公开（公告）日：2004-01-01

  The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the &agr;7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

  本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷类化合物，制备这些化合物的方法以及使用这些化合物进行治疗的方法。这些氮杂双环烷通常是氮杂双环庚烷、氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基是一个5-或6-成员环杂芳基，优选是3-吡啶基和5-嘧啶基，烷基通常是C1-4烷基。1-氮杂双环烷的3-位取代基是一个含有羰基的基团，例如酰胺、碳酸酯、脲、硫代酰胺、硫代碳酸酯、硫脲或类似功能基团。这些化合物在尼古丁型乙酰胆碱受体(nAChRs)上表现出活性，特别是α7 nAChR亚型，并且对调节神经递质传递和与神经递质有关的配体释放具有用处。还公开了用于预防或治疗中枢神经系统（CNS）疾病等疾病和疾病的方法，这些疾病和疾病以正常神经递质传递的改变为特征。还公开了用于治疗炎症、自身免疫疾病、疼痛和过度新生血管化的方法，例如与肿瘤生长相关的新生血管化。
• Intranasal cyclic peptide formulations
  申请人：——

  公开号：US20010038824A1

  公开（公告）日：2001-11-08

  The present invention relates to a nasally administrable composition of a physiologically active cyclic peptide and pharmaceutically acceptable salts thereof that is prepared by homogeneously dispersing a physiologically active cyclic peptide such as antifungal cyclic peptides (aerothricins, echinocandin analogs, pneumocandin analogs, and aureobacidines), antibacterial cyclic peptides (e.g. vancomycin, daptomycin), cyclosporin A, lanreotide, vapreotide, vasopressin antagonist (U.S. Pat. No. 5,095,003) and eptifibatide in unique carrier, i.e. a physiologically acceptable powdery or crystalline carrier containing a water insoluble polyvalent metal carrier, or organic carrier having a mean particle size of 20 to 500 &mgr;m, in the presence or absence of an absorption enhancer and by homogeneously adsorbing onto the carrier, and its use for therapeutic treatment of disease such as systemic fungal infections by intranasal administration. The composition can be nasally administered in powder form.

  本发明涉及一种鼻腔可给药的生理活性环肽及其药学上可接受的盐的组合物，该组合物通过将生理活性环肽（如抗真菌环肽（气菌素、伊曲康定类似物、肺孢子菌素类似物和金黄色细菌素）、抗菌环肽（如万古霉素、达托霉素）、环孢霉素A、兰雷罗肽、瓦普雷罗肽、抗利尿激素拮抗剂（美国专利号5,095,003）和依普利贝肽）均匀分散在独特的载体中制备而成，即含有水不溶性多价金属载体或平均粒径为20至500微米的有机载体的生理上可接受的粉状或结晶载体中，存在或不存在吸收增强剂，通过均匀吸附到载体上，并用于通过鼻内给药治疗疾病，如系统真菌感染。该组合物可以以粉剂形式鼻腔给药。
• Pharmaceutical compositions and methods for use
  申请人：——

  公开号：US20030045523A1

  公开（公告）日：2003-03-06

  Pharmaceutical compositions include aryl substituted amine compounds, and in particular, carbon-linked aromatic azabicyclo compounds, and in particular, aromatic alkylene azabicyclo compounds and aromatic alkyl azabicyclo compounds.

  药物组合物包括芳基取代胺化合物，特别是碳链芳香族氮杂双环化合物，特别是芳基烷基氮杂双环化合物和芳基烷基氮杂双环化合物。